Beginning July 1 and running through the end of 2027, a new pilot program will allow some Medicare Part D prescription plan members who want to shed excess pounds and maintain weight loss to get Wegovy injections and tablets, Foundayo tablets or the Zepbound KwikPen for a $50 monthly copay
Conn AR, Fell DI, Steele RD
Patrick L (2002) Nonalcoholic fatty liver disease: Relationship to insulin sensitivity and oxidative stress
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
Super welcoming, super clean, all staff are friendly, and theyre very knowledgeable and helpful
Prior authorization: what your doctor documents Most plans require prior authorization